AMD market report forecasts strong growth and dominant role for Novartis

5 April 2018

A new report finds that pharmaceutical sales within the age-related macular degeneration (AMD) markets could reach $11.5 billion across the seven major markets by 2026, growing at nearly 9% on an annual basis.

Novartis has acquired strong Phase III data for its AMD candidate RTH258 (brolucizumab). Meanwhile, Regeneron's (Nasdaq: REGN) patent for Eylea (aflibercept) expires in 2020 in the EU, where it's licensed to Bayer (BAYN: DE), and 2021 in the USA.

GlobalData analyst Edit Kovalcsik said: “We expect that with the launch of brolucizumab in the wAMD market, Novartis will offset the losses to Eylea and regain dominance in the AMD market.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK